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Background: Depressive symptoms and sleep disturbances disproportionately affect midlife 
women, with long-term health consequences to women’s health. Previous studies have reported 
that depressive symptoms are associated with individual components of sleep, but this approach 
does not consider the 24-hour integration of nocturnal sleep, circadian timing, and daytime 
functioning. Additionally, the mechanisms underlying the association have not been elucidated. 
The current study examines the longitudinal association between depressive symptoms and a 
multidimensional construct, sleep health, as well as evaluates body mass index and physical 
activity as possible pathways explaining this relationship. 
Methods: Depressive symptoms were assessed at 6-9 annual assessments in 302 midlife women 
(52.1±2.1y) from the Study of Women’s Health Across the Nation. Six months later, wrist 
actigraphy (M = 25.8 days) and validated questionnaires were collected, which were used to 
assess components of sleep health: efficiency, duration, timing (wake time minus sleep onset, 
divided by two), regularity (standard deviation of timing), alertness, and satisfaction. Each 
component was dichotomized based on evidence-based cut-off scores, and the six components 
were summed; higher values indicated better sleep health. Associations between depressive 
symptoms and sleep health were evaluated using linear regression for composite sleep health and 
logistic regression for each component of sleep health, adjusting for age, race, study site, 
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menopausal status, vasomotor symptoms, apnea-hypopnea index, and use of medications that 
affect sleep. Parallel multiple mediation was used to test whether body mass index (BMI) and 
physical activity mediated the association between depressive symptoms and sleep health. 
Results: Higher mean depressive symptoms was associated with poorer sleep health in 
unadjusted (𝛽𝛽 = -0.30, p < .001) and adjusted models (𝛽𝛽 = -0.24, p < .001). Greater variability in 
depressive symptoms was associated with poorer sleep health in unadjusted (𝛽𝛽 = -0.14, p = .02), 
but not adjusted models (p = .16). Physical activity and BMI explained a significant portion of 
the variance in the association between mean depressive symptoms and sleep health. 
Conclusion: Mean depressive symptoms are longitudinally associated with sleep health. 
Depressive symptoms are related to sleep health, in part, through BMI and physical activity, 
suggesting a possible point of intervention. 
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1.0 Introduction 
 
More than 43 million women in the United States were aged 45-54, or midlife, in 2016 (United 
States Census Bureau, 2017), a 17% increase from 2005 (United States Census Bureau, 2007). 
Midlife women experience the menopausal transition, characterized by the gradual cessation of 
menstruation and ovarian functioning (North American Menopause Society, 2007), and its 
concomitant mood changes and sleep disturbances lead to an increase in physician visits and 
prescription medications (for review, see Utian, 2005). Chief among the complaints of midlife 
women is sleep disturbances, including insomnia symptoms and poor sleep quality (Woods & 
Mitchell, 2005, 2010), with 40% of women reporting difficulty sleeping (Cirignotta, Mondini, 
Zucconi, Luigi Lenzi, & Lugaresi, 1985; Dennerstein, Dudley, Hopper, Guthrie, & Burger, 2000; 
Kravitz et al., 2008, 2017). Not only are sleep disturbances bothersome to these women, but they 
are also prospectively associated with health problems such as cardiovascular disease 
(Cappuccio, Cooper, Delia, Strazzullo, & Miller, 2011) and mortality (Cappuccio, D’Elia, 
Strazzullo, & Miller, 2010). Understanding what may lead to sleep disturbances in midlife 
women is crucial for improving sleep, and in the longer term, lowering risk for these health 
outcomes. 
Compelling evidence suggests that depressive symptoms may be prospectively associated 
with sleep disturbances in midlife women (Lampio, Saaresranta, Engblom, Polo, & Polo-
Kantola, 2016). The association between depressive symptoms and sleep disturbances may be 
linked by pathways such as body mass index (BMI) and physical activity, as depressive 
symptoms has been shown to precede these factors (Luppino et al., 2010; Roshanaei-
Moghaddam, Katon, & Russo, 2009) and each has been associated with subsequent poorer sleep 
(Resta et al., 2003; Kredlow et al., 2015). Notably, depressive symptoms and these mediators 
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impact a variety of dimensions of sleep (i.e. sleep architecture, continuity, and timing). However, 
previous studies infrequently account for multiple dimensions simultaneously or considered 
measures of sleep-wake patterns. The current study assesses the longitudinal relationship 
between depressive symptoms and sleep health, a multidimensional construct which includes 
measures of sleep, sleep-wake timing, and next-day functioning. Examining sleep health allows 
for a better understanding of the global impact depressive symptoms may have on sleep during 
the menopausal transition.  
1.1 Sleep in midlife women 
 
Self-reports of insomnia have been shown to increase in prevalence during midlife for women. 
Midlife women report greater sleep disturbances than their age-matched male counterparts 
(Cirignotta et al., 1985). This may, in part, be due to physiological, psychological, and social 
changes during the menopausal transition, as women move from premenopause (regular 
menstrual periods and no change in flow or length of period), to perimenopause (menstrual 
period in the past three to 12 months), and finally to postmenopause (no menstrual period in the 
past 12 months; Stages of Reproductive Aging Workshop (STRAW) criteria, Harlow et al., 
2012). Insomnia symptoms, defined as subjective difficulty falling asleep, difficulty maintaining 
sleep, or early morning awakenings, were more prevalent at later stages of the menopausal 
transition, according to a meta-analysis of 24 cross-sectional studies (Xu & Lang, 2014), a 
systematic review of eight longitudinal studies (Xu, Lang, & Rooney, 2014), and a more recent, 
13-year follow-up study (Kravitz et al., 2017).  
A less consistent literature has examined the association between menopausal status and 
polysomnography (PSG) assessed sleep. Studies have reported that later menopausal stages were 
associated with more (Xu et al., 2011) or less (Young, Rabago, Zgierska, Austin, & Laurel, 
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2003) wake after sleep onset, longer total sleep time (Sowers et al., 2008; Young et al., 2003), 
and higher percentage of non-rapid eye movement (NREM) Stages 3 and 4 sleep (Lampio et al., 
2017; Sowers et al., 2008; Young et al., 2003). Some studies reported no association between 
menopausal status and these measures of sleep (Campbell et al., 2011; Shaver, Giblin, Lentz, & 
Lee, 1988; Xu et al., 2011). In sum, this literature suggests that while there is inconsistent 
evidence of differences in PSG-assessed sleep, there is consistent evidence of higher prevalence 
of self-reported insomnia symptoms at later stages of the menopausal transition. Understanding 
what may precede these changes is important, as sleep disturbances are associated with negative 
health outcomes.  
1.2 Depressive symptoms and sleep 
 
One modifiable risk factor for sleep disturbances in midlife women during the menopausal 
transition may be depressive symptoms. Prevalence of major depressive disorder, a diagnosis 
defined by clinically significant depressive symptoms, doubles from pre-menopause to 
perimenopause in women with no history of depression (Cohen, Soares, Vitonis, Otto, & 
Harlow, 2006), and is about five times higher at postmenopause (Woods & Mitchell, 2005) 
compared to age-matched men and women (Substance Abuse and Mental Health Services 
Administration, 2016).  
Depressive symptoms have been shown to be associated with sleep disturbances in 
midlife women. In models assessing sleep and depressive symptoms concurrently over time, 
higher depressive symptoms were associated with worse sleep quality over eight-year follow-up 
(Pien, Sammel, Freeman, Lin, & DeBlasis, 2008) and more frequent insomnia symptoms over 
eight-year follow-up (Woods & Mitchell, 2010). In another study, higher depressive symptoms 
were associated with greater odds of nocturnal awakenings and greater odds of next-day 
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tiredness at five-year follow-up (Lampio et al., 2016). However, these studies do not exclude 
participants who are depressed at the time of the sleep assessment. This is critical, as depressive 
symptoms are highly correlated over time, and thus temporal conclusions may be confounded by 
high depressive symptoms at the time of the sleep study (Bromberger et al., 2005). 
Variability in depressive symptoms over time may also be an important factor for 
understanding sleep disturbances in midlife women. For example, in a study examining 
correlates of MDD, women who had persistent and/or recurrent episodes of MDD were eight 
times more likely than those with a single episode of MDD to report sleep problems 
(Bromberger et al., 2016; cf. Brown et al., 2014). Inconsistent with this evidence, another study 
reported that mean, but not slope, of depressed mood (“feeling sad or blue”) over 10 years was 
associated with more insomnia symptoms (Woods & Mitchell, 2010). A second study reported 
that change in depressive symptoms at five-year follow-up was not associated with insomnia 
symptoms (Lampio et al., 2016). This preliminary evidence suggests that evaluating the 
variability in depressive symptoms may be important for understanding sleep disturbances. 
Based on this evidence, it seems that the increasing risk of depressive symptoms (Cohen 
et al., 2006) may be partially driving the increase in prevalence of sleep disturbances during the 
menopausal transition specifically and midlife women in general (Kravitz et al., 2008, 2017). 
Evaluating if depressive symptoms are longitudinally associated with a multidimensional 
construct of sleep is important for integrating these literatures on sleep satisfaction, quality, and 
continuity. Moreover, understanding why depressive symptoms are longitudinally associated 
with sleep disturbances in midlife women is useful for the evaluation of multiple treatment 
targets. 
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Many studies (which have resulted in three meta-analyses of approximately forty studies 
in the past seven years, Baglioni et al., 2011; Bao et al., 2017; Li et al., 2016) have examined the 
associations between depressive symptoms and sleep. Less understood is why there is this 
consistent relationship. Given this dearth of research, putative mediators were carefully selected 
from a list of possible factors based on: 1) consistent literature linking depressive symptoms to 
the factors; 2) literature linking these factors to sleep; 3) their importance during the context of 
midlife; and 4) their demonstrated impact on future quality of life and health and functioning. 
Weight and physical activity each meet these criteria, and also are inversely related in that 
changes in physical activity can lead to weight loss, and weight gain can lead to a decreased 
interest in physical activity (Sternfeld et al., 2005).  
1.3 Weight as a mediator of the association between depressive symptoms and sleep 
1.3.1 Depressive symptoms and body mass index. In the United States, two-thirds 
of women aged 45-54 are overweight or obese (2011-2014; CDC, 2016). Midlife women often 
experience an increase in weight (approximately 1.5 pounds per year; Karvonen-Gutierrez & 
Kim, 2016), as well as a change in the distribution of fat. Premenopausal women have relatively 
greater subcutaneous adipose tissue (Karvonen-Gutierrez & Kim, 2016), while post-menopausal 
women have greater visceral adipose tissue (compared to their own premenopausal levels, as 
well as age-matched premenopausal women; Lovejoy, Champagne, De Jonge, Xie, & Smith, 
2008). This redistribution of the location of adipose tissue is medically relevant, because 
visceral, but not subcutaneous, adipose tissue has been associated with metabolic risk factors 
(Fox et al., 2007). In sum, changes in weight and its distribution occurring during midlife for 
women may have consequences for health and functioning. 
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One reported antecedent of weight gain and weight redistribution in midlife is depressive 
symptoms. Depressive symptoms have been prospectively associated with obesity in a meta-
analysis of 15 prospective studies (Luppino et al., 2010). In studies of midlife women 
specifically, depressive symptoms  have been cross-sectionally associated with higher BMI  
(Freeman et al., 2009; Blümel et al., 2015) and greater visceral adipose tissue (Everson-Rose et 
al., 2009; Murabito, Massaro, Clifford, Hoffmann, & Fox, 2013). Depression may result in 
subsequent weight gain and redistribution due to a variety of the symptoms of depression, such 
as increased appetite, fatigue or loss of energy, or psychomotor retardation (American 
Psychiatric Association, 2013).  
 1.3.2 Body mass index and sleep. High BMI has been acknowledged clinically as an 
important determinant of sleep quality for decades. Primarily, this is because obesity is a strong 
predictor of obstructive sleep apnea (OSA; Epstein et al., 2009), characterized by pauses in 
breathing throughout the night. However, higher BMI has also been associated with sleep 
disturbances above and beyond sleep apnea. For example, in individuals without OSA, higher 
BMI has been associated with self-reported excessive daytime sleepiness, greater PSG-assessed 
WASO and lower sleep efficiency (Resta et al., 2003; Vgontzas et al., 1998). In a study of 
midlife women (controlling for apnea-hypopnea index), actigraphy- and diary-assessed short 
sleep duration was cross-sectionally associated with greater BMI (Appelhans et al., 2013). 
Bariatric surgery, one intervention to aid in weight loss, has been shown to improve self-reported 
sleep quality (Dixon, Schachter, & Brien, 2001; Toor, Kim, & Buffington, 2012) increased sleep 
duration (Toor et al., 2012), and decrease daytime sleepiness (Dixon et al., 2001). 
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1.4 Physical activity as a mediator of the association between depressive symptoms 
and sleep. 
 
1.4.1 Depressive symptoms and physical activity.  In 2015, less than half of 
women aged 45-54 were meeting federal guidelines for leisure-time aerobic activity (Center for 
Disease Control and Prevention, 2016), defined as 150 minutes of moderate or 60 minutes of 
vigorous exercise per week (e.g. Haskell et al., 2007). Engagement in physical activity provides 
widespread benefits to physical and mental health functioning (for review, see Penedo & Dahn, 
2005). In midlife women specifically, physical activity has been shown to be associated with 
feelings of self-determination and confidence (Janssen, Dugan, Karavolos, Lynch, Powell, 2014), 
weight loss (Sternfeld et al., 2005), and a prospective decrease in psychosocial and physical 
symptoms associated with menopause (McAndrew et al., 2009). In randomized controlled trials, 
exercise intervention enhanced positive affect and decreased menopausal symptoms (e.g. hot 
flashes; Elavsky & McAuley, 2007), and increased fitness levels in a dose-response style 
(Church et al., 2007). This literature suggests that midlife women may benefit from physical 
activity in terms of menopausal symptoms and mental health. However, poor mental health – and 
in particular, depressive symptoms – may make it difficult to engage in physical activity. 
In a review of 11 studies, depressive symptoms were prospectively associated with 
decreased physical activity levels (Roshanaei-Moghaddam, Katon, & Russo, 2009). In particular, 
these studies reported the most robust association between an increase over time in depressive 
symptoms (i.e. worsening symptoms) and a decrease in physical activity. These results have been 
replicated (Da Silva et al., 2012; Pereira, Geoffroy, & Power, 2014), as well as extended. For 
example, the relationship between depressive symptoms and cardiovascular disease-related 
mortality was mediated by physical activity (Win et al., 2011). Further, there may be a dose-
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response relationship between the two, such that each additional symptom of depression is 
associated with lower odds of engaging in physical activity (Pereira et al., 2014). 
1.4.2 Physical activity and sleep. A meta-analysis of 66 studies has indicated that 
physical activity benefits sleep quality, sleep latency, sleep efficiency, and total sleep time 
(Kredlow et al., 2015). During the menopausal transition, greater physical activity was associated 
with better sleep quality, but was unassociated with actigraphy-assessed sleep (Lambiase & 
Thurston, 2013). In another study, greater physical activity was associated with better sleep 
quality, continuity, quantitative EEG depth (i.e. high delta, low beta spectral power), and lower 
odds of insomnia (Kline et al., 2013).  
1.5 Sleep health 
 
Depressive symptoms, obesity, and physical activity seem to influence multiple dimensions of 
sleep during the menopausal transition. Previous studies sometimes report on multiple sleep 
measures, but do not consider these measures concurrently. Sleep health is a multidimensional 
construct of the 24-hour experience of sleep, considering nighttime sleep and timing, and 
daytime functioning (Buysse, 2014). The six dimensions of sleep health include: Regularity, or 
the consistency of sleep midpoint; Satisfaction, or the self-report rating of sleep quality; 
Alertness, or the ability to maintain wakefulness during the day; Timing, or the placement of 
sleep within the 24-hour day; Efficiency, or the ability to initiate and maintain sleep; and 
Duration, or quantity of sleep. The mnemonic “RU SATED?” may be used to remember these 
six components. 
Each of these six dimensions is affected by depressive symptoms and the reviewed 
mediators. There is evidence that depressive symptoms affects all six domains: regularity 
(Germain & Kupfer, 2008; McClung, 2013), satisfaction (Pien et al., 2008), alertness (Lampio et 
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al., 2016), timing (Kitamura et al., 2010), efficiency (Lampio et al., 2016), and duration (long, 
Patel, Malhotra, Gottlieb, White, & Hu, 2006; insomnia, Bao et al., 2017; Li et al., 2016). There 
is literature suggesting that greater BMI negatively affects alertness, efficiency, duration 
(Vgontzas et al., 1998), and timing (Baron, Reid, Kern & Zee, 2011), while greater physical 
activity positively affects satisfaction, efficiency, duration (Kredlow et al., 2015), timing 
(Tworoger et al., 2003). Thus, sleep health as an outcome extends the literature by providing an 
understanding of how depressive symptoms affect multiple domains of sleep simultaneously. 
Only two previous studies, to our knowledge, have evaluated the construct of sleep health 
(Buysse, 2014). One reported that poorer sleep health was associated cross-sectionally and 
prospectively with clinically significant depressive symptoms (Furihata et al., 2017), and the 
other demonstrated that childhood trauma was associated with poorer diary- and actigraphy-
assessed sleep health in adulthood (Brindle et al., 2018). Together, this limited literature suggests 
that sleep health may be a robust measure integrating information from several measures of the 
individual’s sleep-wake experience. 
1.6 The current study 
 
Evidence supports an examination of the prospective association between depressive symptoms 
and sleep health in midlife women, as well as evaluating why this association exists by including 
BMI and physical activity in the model. The present study assessed the association between 
depressive symptoms and sleep health, as well as BMI and physical activity as explanatory 
pathways of this association. 
The current study had two aims: (1) to evaluate longitudinal associations between 
depressive symptoms and sleep health; and (2) to examine mediators of the longitudinal 
association between depressive symptoms and sleep health. It was hypothesized that: (1a) greater 
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mean level depressive symptoms will be associated with poorer sleep health; (1b) greater 
variability in depressive symptoms across assessments will be associated with poorer sleep 
health; and (2) BMI and physical activity will partially contribute to the association between 
mean depressive symptoms and sleep health. Results of this study will be useful for 
understanding modifiable determinants of sleep health during the menopausal transition. 
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2.0 Methods 
 
The current study used longitudinal data from the Study of Women’s Health Across the Nation 
(SWAN; hereafter referred to as the core SWAN study) for measures of depressive symptoms, 
BMI, and physical activity. The SWAN is a longitudinal study designed to assess the correlates 
of the menopausal transition in the United States. The baseline examination of the core SWAN 
study was conducted at seven sites in 1996 and 1997. Women were eligible at baseline if they 
were 42-52 years of age, reported a menstrual period within the past three months, had an intact 
uterus, and at least one ovary. Women were ineligible if they were pregnant, breastfeeding, or 
reported exogenous hormone use (Avis & Crawford, 2001). Following baseline, core SWAN 
assessments occurred approximately yearly.  
During one of the follow-up visits 5-8 (2001-2006) of the core SWAN study, participants 
at four sites (Pittsburgh, PA; Chicago, IL; Detroit, MI; and Oakland, CA) were approached about 
participation in the ancillary SWAN Sleep Study. Exclusion criteria for the ancillary SWAN 
Sleep Study were noncompliance with core SWAN procedures; current oral corticosteroid use; 
current chemotherapy or radiation; regular shift work; diagnosis of sleep apnea; or consumption 
of more than four alcoholic drinks per day. The SWAN Sleep Study included 370 European 
American, African American, and Chinese American women, and collected diary- and 
actigraphy-assessed sleep over a 35-day period, or the length of the participant’s menstrual cycle, 
whichever was shorter. Wrist actigraphy data was used for the calculation of sleep health, where 
possible, as self-report may be affectively biased (Lauderdale et al., 2008), and most PSG 
visually scored sleep variables demonstrate poor short-term stability within-person (Israel, 
Buysse, Krafty, Begley, Miewald, & Hall, 2012). Figure 1 shows how data from core SWAN 
and the ancillary SWAN Sleep Study were used for the purposes of the current study. 
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2.1 Participants 
Participants for the current study were 302 women who participated in the ancillary SWAN 
Sleep Study who had full data for analyses assessing the association between depressive 
symptoms and sleep health (Figure 2). We removed participants from analyses with less than 4 
nights of actigraphy (n = 42), missing Epworth Sleepiness Scale (n = 9), and missing apnea 
hypopnea index data (n = 17).  
2.2 Measures 
2.2.1 Depressive symptoms. We measured depressive symptoms as our primary 
variable of interest across six to nine core SWAN study assessments (see Figure 1 for data 
structure details). Six to nine assessments were used because only data prior to the SWAN Sleep 
Study were used, which occurred between follow-up visits five through eight. Depressive 
symptoms were assessed using the 20-item Center for Epidemiologic Studies Depression Scale 
(CES-D; Radloff, 1977). The sleep disturbances item (“My sleep was restless”) was removed, to 
avoid confounding with the outcome of interest, sleep health. The CES-D was administered 
orally by core SWAN study staff at each assessment, and adapted from the original “over the 
past two weeks” timeframe to “during the past week.” Scores for each item range from 0 (less 
than once a day) to 3 (most or all of the days; 5-7 days), and the overall scores for the current 
study range from 0 (lowest) to 51 (highest possible score, excluding the sleep item). In a non-
clinical population, the CES-D has good internal consistency (𝛼𝛼 = 0.85) and adequate validity 
(self-report compared to nurse-clinician rating r = 0.56; Radloff, 1977). In midlife women, a 
single-factor structure fits the data well (Knight, Williams, McGee, & Olaman, 1997). Mean 
level of depressive symptoms was calculated as the average score on the CES-D across annual 
core SWAN study assessments prior to the ancillary SWAN Sleep Study. Variability in 
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depressive symptoms was calculated as the standard deviation of the CES-D score across core 
SWAN Study assessments prior to the ancillary SWAN Sleep Study.  
 2.2.2 Sleep health. Sleep health was calculated by wrist actigraphy-assessed sleep, 
efficiency, timing, regularity, and duration, and self-reported alertness and satisfaction, collected 
during the ancillary SWAN Sleep Study. Duration was defined as the total minutes of sleep; 
efficiency was defined as the total minutes of sleep following sleep onset divided by the total 
minutes of time in bed, multiplied by 100; timing was defined as the midpoint of sleep, 
calculated as bedtime subtracted from waketime, divided by two, then this value is added to 
bedtime; regularity was defined as the standard deviation of the individual’s sleep midpoint; 
satisfaction was defined as the average self-reported “restedness” after a night of sleep using a 
daily sleep diary; and alertness was defined as self-reported alertness on the Epworth Sleepiness 
Scale (Johns, 1991). Duration, efficiency, timing, regularity, and satisfaction were calculated as 
the average or standard deviation of daily data. Alertness based on the Epworth Sleepiness Scale 
was assessed once. 
Each continuous sleep health variable was dichotomized, with 0 indicating poor sleep 
health and 1 indicating good sleep health. The cut-offs for each sleep health variable were 
created a priori based on empirical literature. For details on the referenced studies and the 
specific cut-points, see Table 1. 
2.2.3 Mediators. Physical activity and BMI were evaluated as potential mediators 
linking mean depressive symptoms with sleep health.  For clear temporal precedence in this 
model, we assessed depressive symptoms before the mediators, and the mediators were assessed 
before the SWAN Sleep Study. For all participants, mean depressive symptoms were averaged 
across four core SWAN Study visits (baseline through follow-up visit 3). An average of two 
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years later (range: 1.4-2.7 yr), BMI and physical activity were measured in the core SWAN 
Study (follow-up visit 5). The SWAN Sleep Study occurred on average two years later (follow-
up visits 5-8; range: 0.3-3.45 yr). Due to missing data for BMI and KPAS at follow-up visit 5, 
which were not included in aim 1 of the study, the total sample size for the mediation model is 
271. 
2.2.3.1 Body mass index. Core SWAN study staff measured height (meters) and weight 
(kilograms) at follow-up visit 5. BMI was calculated as kilograms divided by meters squared. 
2.2.3.2 Physical activity. Physical activity was measured using a modified version of 
the Kaiser Physical Activity Scale (KPAS; Sternfeld, Ainsworth, & Quesenberry, 1999). This 
scale was specifically designed for assessing physical activity in midlife women, as they engage 
in more than recreational physical activity alone. More specifically, the KPAS assessed levels of 
activity within the past 12 months of household/caregiving (e.g. cooking and cleaning, caring for 
a young child or older adult), active living (e.g. biking to work), and sports/exercise (e.g. playing 
a sport or exercising). Scores on each of these three domains ranges from 1-5, with higher scores 
indicating higher levels of activity. The KPAS has high one-month test-retest reliability (r = 0.79 
to 0.81) and moderate correlation with percent body fat and VO2 peak (r = -0.30 to -0.59, 0.34 to 
0.76, respectively; Ainsworth, Sternfeld, Richardson & Jackson, 1999).  
2.2.4 Covariates. The following measures were included in the adjusted model as 
covariates: age, site, race/ethnicity, menopausal status, percent of nights that participants 
reported vasomotor symptoms, proportion of visits preceding SWAN Sleep Study that 
participants reported using antidepressants, percent of nights that participants reported using 
medications that affect sleep, and the apnea-hypopnea index (AHI). These measures were 
selected based on their known influences on depressive symptoms, sleep, or both in previous 
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studies of midlife women. Menopausal status was assessed at the core SWAN visit preceding the 
SWAN Sleep Study. The proportion of visits that participants reported using antidepressants was 
assessed at all core SWAN visits preceding the SWAN Sleep Study. All other covariates were 
assessed at the SWAN Sleep Study.  Age and race/ethnicity data were based on self-report. Site 
was a categorical variable indicating where participation took place (Pittsburgh, PA; Chicago, 
IL; Detroit, MI; and Oakland, CA). 
2.2.4.1 Menopausal status. Menopausal status was determined based on self-reported 
bleeding patterns according to the STRAW guidelines (Harlow et al., 2012). Specifically, the 
premenopause/early perimenopause category was defined as women who reported bleeding in 
the past three months and whose menstrual periods were regular or somewhat irregular. Late 
perimenopause represented women who had bleeding in the last 12 months prior to her visit but 
no bleeding in the past three months. Natural postmenopause includes women who had no 
bleeding in the 12 months prior to the visit. Unknown status characterized women whose 
menopausal status could not be determined. No women in the SWAN Sleep Study underwent 
bilateral salpingo oophorectomy. 
2.2.4.2 Vasomotor symptoms. Vasomotor symptoms, or hot flashes, have been shown 
to increase in both frequency and severity during midlife (Woods & Mitchell, 2005) due to 
changes in follicular stimulating hormone levels (Gold et al., 2004, 2007). At the ancillary 
SWAN sleep study, women reported the frequency (“How many times did you experience these 
symptoms last night?”, with categories of 0, 1, 2, 3, 4, “5 or more”, and “all night”) of their hot 
flashes, cold sweats, and night sweats. These variables are frequently aggregated in other studies 
of vasomotor symptoms (Politi, Schleinitz, & Col, 2008). Previous studies from the core SWAN 
study have reported that these three variables have high single-factor loadings (hot flashes, 0.68-
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0.78; cold sweats, 0.73; night sweats, 0.75-0.81; Gold et al., 2004, 2006). The percent of nights 
during which women reported vasomotor symptoms during the SWAN sleep study was included 
as a covariate. 
2.2.4.3 Medications that affect sleep. Participants reported on their daily medication 
use each night during the SWAN Sleep Study. Medication that is known to affect sleep, even if it 
was not taken for aiding sleep, included the following classes identified by the World Health 
Organization Anatomical Therapeutic Chemical (ATC) classifications: N02A (opioids), N03A 
(antiepileptics), N05B (anxiolytics), N05C (hypnotics and sedatives), N06A (antidepressants), 
and R06A (antihistamines for systemic use). The percent of nights that these medications were 
reported over the sleep study was included as a covariate. 
2.2.4.4 Apnea hypopnea index. Sleep apnea was assessed using in-home 
polysomnography. Equipment included oral-nasal thermistors and nasal pressure for air flow, 
impedence pethysmography to measure abdominal movements, and fingertip oximetry to assess 
oxygen desaturation. The AHI was calculated by identifying apneas and hypopneas pursuant to 
American Academy of Sleep Medicine guidelines (American Academy of Sleep Medicine Task 
Force, 1999). 
2.2.4.5 Antidepressants. At each core SWAN visit, participants reported their use of 
antidepressants (NO6A; monoamine oxidase [MOA] inhibitors, selective serotonin reuptake 
inhibitors [SSRIs], tri- or tetracyclics, and “others”). The proportion of visits preceding the 
SWAN Sleep Study that a woman reported taking one or more antidepressant(s) was included as 
a covariate.  
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2.3 Statistical Analysis Plan 
Descriptive statistics were used to characterize the sample. Linear regression assumptions were 
examined, and AHI was log-transformed to reduce skewness. Univariate analyses for mean and 
variability in depressive symptoms were followed by multiple linear regression models. 
Regression models adjusted for age, site, race/ethnicity, menopausal status, propotion of visits 
preceding SWAN Sleep Study that participants reported using antidepressants, percent of nights 
that the participant reported vasomotor symptoms, percent of nights that the participant reported 
using medications that affect sleep, and log-transformed AHI. Age, antidepressants, percent of 
nights that the participant reported vasomotor symptoms, percent of nights that the participant 
reported using medications that affect sleep, and log-transformed AHI were continuous and 
centered based on the sample’s mean. Site was entered as three dichotomous variables: Chicago, 
IL, Detroit, MI, and Oakland, CA, with Pittsburgh, PA as the reference. Race/ethnicity was 
entered as two dichotomous variables, African Americans and Chinese Americans, with 
European Americans as the reference. Menopausal status was entered as three dichotomous 
variables: late perimenopause, postmenopause, and unknown, with early/perimenopause as the 
reference. 
A post-hoc power analysis of a linear multiple regression (fixed model, assessing R2 
increase) test calculated a conservative estimate of the power to detect significant effects in the 
current study (G-Power; Faul, Erdfelder, Buchner, & Lang, 2008). This test indicated that there 
was 100% power to detect an effect size greater than or equal to 0.08 with 280 participants and 
14 total predictors in the model, and 82% power to detect an effect size greater than or equal to 
0.03. In a similar study assessing depressive symptoms and self-reported sleep during the 
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menopausal transition at five-year follow-up, effect sizes ranged from 0.16-0.24 (for nocturnal 
awakenings and daytime sleepiness, respectively; Lampio et al., 2016). 
Sleep health is a relatively new concept, with limited literature on the best modeling 
strategy. Thus, we evaluated a series of models of sleep health for this study. First, an equally 
weighted composite score of sleep health (ranging from 0 to 6, with higher scores indicating 
better sleep health) was an outcome in a multiple linear regression model. “Equally weighted” 
refers to the fact that each component of sleep health has a weight of one. Next, we evaluated 
each component of sleep health as an outcome in six separate binary logistic regression models 
(0 was poor sleep health, 1 was good sleep health). These dichotomous variables were used to 
evaluate the “subscales” of the composite sleep health measure, and because they more closely 
represent a checklist that could be used in a clinical setting (Buysse, 2014). Equally weighted 
sleep health and assessment of sleep health components are methods that have been previously 
employed in studies of sleep health (Brindle et al., 2018; Furihata et al., 2017).  
We also evaluated a variably weighted sleep health score, because using equally 
weighted sleep health scores assumes that each component is equally important. Variably 
weighted sleep health was quantified in four steps: (1) we re-coded each sleep health component 
so that 0 was good sleep health, 1 was poor sleep health; (2) we entered mean depressive 
symptoms as the independent variable and each sleep health component as the outcome in six 
binary logistic regressions; (3) we multiplied the odds ratio for each component by its 
corresponding dichotomous sleep health component; (4) we summed the weighted sleep health 
components (see Supplemental Table 1). The equally weighted and variably weighted sleep 
health scores in the current study were highly correlated (r = 0.99), and so we were unable to test 
which sleep health score was more strongly associated with mean depressive symptoms. Because 
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of this high correlation, it was not possible to compare our models for equally weighted and 
variably weighted outcomes. That is, there would be no difference in regression model estimates. 
In an exploratory aim, we evaluated whether variability in depressive symptoms 
moderated the longitudinal association between mean level of depressive symptoms and sleep 
health. This is based on the notion that variability and mean symptoms may be synergistic, such 
that the combination of high variability and high mean symptoms would be associated with the 
poorest sleep health, compared to either variable in isolation (e.g. high mean, low variability). 
There was evidence of heteroscedasticity (non-constant variance in the residuals) between 
variability and mean depressive symptoms using the modified Levene’s test (Gastworth, Gel, & 
Miao, 2009). To address this, weighted least squares regression was used for the moderation 
analysis. The interaction term and predictors were centered on the sample’s mean. Each main 
effect was entered, followed by the interaction term, and then adjustment for covariates. The 
linear regression models, binary logistic regression models, and moderation analyses were 
conducted in IBM SPSS Statistics software (version 25).  
To test whether BMI and physical activity mediated the longitudinal association between 
mean depressive symptoms and sleep health, we evaluated a parallel multiple mediation model. 
We assessed mean depressive symptoms across four visits, two years later we measured the 
mediators at one time point, and then two years later we assessed sleep health in the SWAN 
Sleep Study. The R package bmem (Zhang, 2014) was used, which uses bootstrapping (n = 
1000) for estimates, standard errors, and bias-corrected confidence intervals. Variables were z-
scored to calculate standardized beta coefficients. Bmem does not calculate p-values; confidence 
intervals that do not contain 1 are significant. 
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In a series of secondary analyses presented in supplementary tables and figures, we report 
pooled estimates from multiple imputation, a strategy used to account for some of our missing 
data. Specifically, we imputed missing CES-D data occurring at any visit prior to the 
participant’s sleep study (n = 53 were missing CES-D data at one or more visits), missing BMI 
(n = 14) and KPAS (n = 21) data at follow-up visit five, and missing AHI data at the SWAN 
Sleep Study (n = 17). We did not to impute missing actigraphy data or Epworth Sleepiness Scale 
values, as we did not have multiple visits from which to impute and these comprised our 
outcome of interest. Our sample size for these supplementary analyses is 319 participants for aim 
1, and 286 participants for aim 2 (mediation models). 
Based on a low level of missingness per variable (< 15%) and desired power of 80%, the 
number of imputations recommended based on Monte Carlo simulations is 20 (Graham, 
Olchowski, & Gilreath, 2007). We specified a multiple imputation model with linear terms (no 
interactions). Minimum and maximum values were specified for all imputed variables to 
preclude impossible values (e.g. a negative BMI value). Variables that were included that could 
contribute to imputation were: CES-D and BMI from baseline through visit 8; KPAS from 
baseline, visit 3, 5, and 6, AHI, age, race, education, employment status, income, level of 
perceived financial strain, marital status, perception of general health, and quality of life. These 
predictors were included as plausible contributors to missing data and/or to information about the 
missing value. The resulting multiple imputation dataset contains 20 datasets of 319 cases each 
with no missing data on the variables specified, for a total of 6,380 cases. 
To test for convergence, we compared the observed (dataset created by listwise deletion, 
n = 280) descriptive statistics to the imputed (pooled values from twenty datasets with no 
missing data, n = 5940) descriptive statistics. Stuart and colleagues (2009) have suggested that 
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imputed data has successfully converged if observed compared to imputed means are less than 
two standard deviations apart, and if the ratio of variance is between 0.5 and 2.0. Supplemental 
Tables 2 and 3 present the observed and imputed descriptive statistics for CES-D, BMI, KPAS, 
and AHI. All variables demonstrated successful convergence.  
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3.0 Results  
3.1 Participant characteristics 
As shown in Table 2, the sample was composed of 112 African American, 50 Chinese American, 
and 140 white women with an average age of 52.1± 2.1. Most of the sample (61.9%) were 
premenopausal or early perimenopausal, 19.2% of the sample were late perimenopausal, and 
12.6% were post-menopausal. The average length of follow-up from baseline to the visit 
preceding the SWAN Sleep Study was 5.7 years (SD = 0.7, range = 4.1-7.2 yr). The average 
length of time between the visit preceding the SWAN Sleep Study and the SWAN Sleep Study 
was 5.6 months (SD = 4.3 months, range = 0 months – 2 years). The average mean depressive 
symptoms score on the CES-D was 7.5 ± 6.2, which indicates low depressive symptoms. 
However, 46.5% of the sample met criteria for clinical depressive symptoms (CES-D > 16) at 
one or more visits, and 9.5% of the sample met criteria for more than 50% of their visits. The 
within-person variability in CES-D across visits was 4.5 ± 3.0. The average participant was 
overweight, with an average BMI of 29.8 ± 7.9. The average total physical activity score on the 
KPAS was 7.5 ± 1.7; survey scores range from 0-15.  
Table 3 shows sleep health characteristics, both as continuous variables and based on 
empirically-derived dichotomous cut-offs (cut-offs are shown in Table 1). The average number 
of nights of actigraphy data was 29.2 nights (SD = 7.0). The average participant slept 6.0 hours ± 
0.9, had a sleep efficiency of 78.0% ± 10.2, a sleep midpoint of 3:20 am ± 0:33 with a within-
person standard deviation of midpoint of 0.7±0.3, and reported being moderately rested (2.0 ± 
0.6) and somewhat sleepy (7.7 ± 4.4). Figure 3 shows the distribution of the composite sleep 
health scores, ranging from 0-6, as a function of the percentage of participants with each score. 
Few participants (0.7%) had zero for their sleep health score, and the most common scores were 
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3 (25.4%) and 4 (26.1%). Figure 4 shows the percentage of participants with optimal scores on 
each of the individual sleep health components.  Most participants had optimal sleep health in 
terms of sleep timing (88.6%), regularity (82.5%), and alertness (70.4%). In contrast, only 25% 
of the sample had optimal sleep health for sleep efficiency.  
3.2 Longitudinal association between depressive symptoms and a composite 
measure of sleep health  
 
The longitudinal association between mean depressive symptoms and a composite measure of 
sleep health in hierarchical linear regression models is presented in Table 4. Note that lower 
sleep health scores indicate poorer sleep health. Higher mean depressive symptoms was 
longitudinally associated with poorer sleep health in both unadjusted (𝛽𝛽 = -0.30, p < .001) and 
adjusted models (𝛽𝛽 = -0.24, p < .001). In evaluating covariates, African Americans (𝛽𝛽 = -0.17, p 
= .009) had poorer sleep health compared to European Americans, participants who were late 
perimenopausal (𝛽𝛽 = -0.14, p = .05) had poorer sleep health compared to those who were pre-
/early perimenopausal, and participants with higher AHI (𝛽𝛽 = -0.18, p = .001) had poorer sleep 
health.  
The longitudinal association between variability in depressive symptoms and sleep health 
is presented in Table 5. Variability in depressive symptoms on the CES-D across visits was 
significantly associated with sleep health in the unadjusted (𝛽𝛽 = -0.14, p = .02), but not in the 
adjusted model (𝛽𝛽 = -0.08, p = .16). In the adjusted model, African Americans (𝛽𝛽 = -0.18, p = 
.008) had poorer sleep health compared to European Americans, participants from the Detroit 
site (𝛽𝛽 = -0.16, p = .01) had poorer sleep health compared to participants at the Pittsburgh site, 
and participants with higher AHI (𝛽𝛽 = -0.18, p = .001) had poorer sleep health.  
In our exploratory aim, we evaluated whether variability in depressive symptoms 
moderated the relationship between mean depressive symptoms and sleep health using weighted 
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least squares regression (Table 6). Mean level and variability in depressive symptoms may be 
synergistic, such that higher mean and variability in depressive symptoms are associated with the 
poorest sleep health compared to high levels of one or the other variable. In the unadjusted 
interaction model (Model 3 in Table 6), there was a main effect of mean depressive symptoms (𝛽𝛽 
= -0.29, p = .001), no significant main effect for variability in depressive symptoms (𝛽𝛽 = 0.09, p 
= .32), and no significant interaction between mean and variability in depressive symptoms (𝛽𝛽 = 
0.02, p = .78). Similarly, in the adjusted model, there was a main effect of mean depressive 
symptoms (𝛽𝛽 = -0.27, p = .001), no significant main effect for variability in depressive 
symptoms (𝛽𝛽 = 0.11, p = .19), and no significant interaction between mean and variability in 
depressive symptoms (𝛽𝛽 = 0.01, p = .82). Significant covariates associated with poorer sleep 
heath included being African American (𝛽𝛽 = -0.19, p = .005) or Chinese American (𝛽𝛽 = -0.15, p 
= .05) compared to being European American, participants from the Detroit site (𝛽𝛽 = -0.13, p = 
.05) compared to participants from the Pittsburgh site, participants who were late perimenopausal 
(𝛽𝛽 = -0.15, p = .01) compared to those who were pre-/early perimenopausal, and higher AHI (𝛽𝛽 
= -0.15, p = .01).  
3.3 Mean and variability in depressive symptoms and individual components of 
sleep health 
 
After evaluating associations with a composite measure of sleep health, we modeled each sleep 
health component individually. This method allows one to evaluate which “subscales” may be 
driving significant associations between variables and the composite sleep health measure. Note 
that zero indicates poor sleep health, and one indicates optimal sleep health for the dichotomous 
components of sleep health. In unadjusted binary logistic regression models, higher mean 
depressive symptoms was longitudinally associated with lower odds of optimal self-reported 
sleep satisfaction (OR = 0.90, p < .001), lower odds of optimal self-reported alertness (OR = 
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0.94, p = .001), lower odds of optimal actigraphy-assessed sleep timing (OR = 0.92, p < .001), 
and lower odds of optimal actigraphy-assessed regularity (OR = 0.96, p = .04). Figure 5 presents 
the odds ratios plotted for adjusted models. In adjusted models, higher mean depressive 
symptoms was associated with lower odds of optimal self-reported sleep satisfaction (OR = 0.90, 
p < .001), and optimal self-reported alertness (OR = 0.93, p = .002), but was not significantly 
associated with actigraphy-assessed sleep timing (OR = 0.95, p = .06) or regularity (OR = 0.96, p 
= .09). Mean depressive symptoms was not significantly associated with sleep efficiency or sleep 
duration in unadjusted or adjusted models (ps > .46).  
In the unadjusted model, greater variability in depressive symptoms was significantly 
associated with lower odds of optimal actigraphy-assessed sleep timing (OR = 0.84, p = .002). 
No other association was significant in unadjusted models (ps > .07). In the adjusted models 
presented in Figure 6, greater variability in depressive symptoms was not significantly associated 
with sleep timing (OR = 0.90, p = .07). There was no significant association between variability 
in depressive symptoms and the other components of sleep health in the adjusted models (ps > 
.50).  
3.4 Parallel multiple mediation model 
Next, we evaluated two putative mediators of the association between higher mean depressive 
symptoms and poorer sleep health. To establish temporal precedence, mean depressive 
symptoms were assessed for four visits, two years later we assessed the possible mediators, and 
two years later we assessed sleep health (see Figure 1 for data structure). Statistically, we used 
parallel multiple mediation analyses including physical activity and BMI concurrently as 
mediators. 
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 The mediation model provides information on the longitudinal associations between 
mean depressive symptoms and the mediators, the mediators and sleep health, the indirect effect 
of mean depressive symptoms on sleep health through the path of the mediators, and the 
remaining direct effect of mean depressive symptoms on sleep health that was not explained by 
the mediators. Mediators differ from covariates in two important ways: (1) mediators are 
theorized to explain an association, whereas covariates may be confounders; (2) indirect effects 
allow one to assess the extent to which an association is explained by a mediator, whereas 
adjusted models allow one to assess the extent to which an association remains, after accounting 
for the variance explained by covariates.  
In Figure 7, we present the parallel multiple mediation model. The total direct effect of 
higher depressive symptoms on poorer sleep health was significant (𝛽𝛽 = -0.26, 95% CI [-0.37, -
0.15]). We report that mean depressive symptoms was significantly associated with BMI (𝛽𝛽 = 
0.13, 95% CI [0.03, 0.24]), and body mass index was significantly associated with sleep health 
(𝛽𝛽 = -0.16, 95% CI [-0.26, -0.04]). There was a significant indirect effect of mean depressive 
symptoms on sleep health through BMI (𝛽𝛽 = -0.03, 95% CI [-0.06, -0.01]). Mean depressive 
symptoms was significantly associated with physical activity (𝛽𝛽 = -0.24, 95% CI [-0.34, -0.15]), 
and physical activity was significantly associated with sleep health (𝛽𝛽 = 0.12, 95% CI [0.01, 
0.24]). The indirect effect of mean depressive symptoms on sleep health through physical 
activity was significant (𝛽𝛽 = -0.02, 95% CI [-0.06, -0.01]). Both BMI and physical activity were 
significant mediators of the longitudinal association between mean depressive symptoms and 
sleep health. The direct effect of depressive symptoms on sleep health after accounting for these 
two indirect effects remained significant (𝛽𝛽 = -0.21, 95% CI [-0.32, -0.09]), indicating that some 
of the variance in this association remained unexplained. 
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3.5 Multiple imputation analyses 
In a series of secondary analyses, we imputed data missing from visits preceding the SWAN 
Sleep Study for CES-D, data missing from follow-up visit 5 for BMI and KPAS, and data 
missing from the SWAN Sleep Study for AHI. This increased our sample size from n = 302 to n  
= 319. The estimates for mean and variability of depressive symptoms included imputed values. 
Pooled estimates across 20 imputed datasets are presented in supplemental materials. In Table 
S4, we present a comparison of the sample characteristics for listwise deletion (i.e. our analyses 
up until this point, and the values shown in Table 2) to multiple imputation strategies. Table S5 
similarly compares sleep health characteristics for the listwise deletion dataset (Table 3) to the 
multiple imputation strategy. Mean and standard deviation did not change substantially for 
continuous variables, or for the number and percent with optimal sleep health components. 
 Using the multiple imputation dataset, we analyzed all the models previously reported in 
Tables 4 through 8. The pattern of results was not substantially different in the multiple 
imputation models compared to the listwise deletion models. First, the longitudinal association 
between mean depressive symptoms and variability in depressive symptoms with sleep health 
was assessed (Tables S6 and S7). Mean depressive symptoms was significantly associated with 
sleep health in unadjusted and adjusted models (ps < .001). Variability in depressive symptoms 
was significantly associated with sleep health in unadjusted (p = .02), but not adjusted models (p 
= .17). In the exploratory aim testing whether variability in depressive symptoms moderated the 
longitudinal association between mean depressive symptoms and sleep health, the interaction 
term was not significant in unadjusted or adjusted models (ps > .69, Table S8). Second, we 
evaluated the components of sleep health individually in logistic regression. Higher mean 
depressive symptoms was associated with significantly lower odds of optimal self-reported 
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satisfaction, self-reported alertness, and actigraphy-assessed timing in unadjusted models (ps < 
.001). Figure S1 shows the adjusted logistic regression results for mean depressive symptoms. 
Mean depressive symptoms was significantly associated with lower odds of optimal self-reported 
satisfaction and alertness in adjusted models (ps < .002), but not with sleep timing (p = .07). 
Greater variability in depressive symptoms was associated with significantly lower odds of self-
reported satisfaction (p = .05) and lower odds of optimal actigraphy-assessed sleep timing in the 
unadjusted model (p < .001). Figure S2 shows that variability was not associated with any sleep 
health components in the adjusted models (ps > .06).  
 We also tested whether BMI and physical activity were significant mediators of the 
association between mean depressive symptoms and sleep health (Figure S3). Mean depressive 
symptoms was significantly associated with BMI (𝛽𝛽 = 0.10, 95% CI [-0.01, 0.22]), and BMI was 
significantly associated with sleep health (𝛽𝛽 = -0.17, 95% CI [-0.28, -0.06]).  The indirect effect 
of mean depressive symptoms and sleep health through BMI was significant (𝛽𝛽 = -0.03, 95% CI 
[-0.06, -0.01]. Mean depressive symptoms was significantly associated with physical activity (𝛽𝛽 
= -0.17, 95% CI [-0.28, -0.06]), and physical activity was significantly associated with sleep 
health (𝛽𝛽 = 0.12, 95% CI [0.02, 0.24]). The indirect effect of mean depressive symptoms and 
sleep health through physical activity was significant (𝛽𝛽 = -0.03, 95% CI [-0.06, -0.01]). Thus, 
both BMI and physical activity were significant mediators. The direct effect of mean depressive 
symptoms and sleep health after accounting for the mediators was significant (𝛽𝛽 = -0.14, 95% CI 
[-0.26, -0.03]), indicating that some of the variance in this association remained unexplained.    
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4.0 Discussion 
Depressive symptoms are prospectively linked to sleep disturbances (Bao et al., 2017). Previous 
work has demonstrated that greater depressive symptoms is associated with higher BMI 
(Luppino et al., 2010) and lower levels of physical activity (Roshanaei-Moghaddam, Katon, & 
Russo, 2009)). In a separate body of literature, higher BMI (Resta et al., 2003; Vgontzas et al., 
1998) and lower levels of physical activity (Kredlow et al., 2015) have been linked to sleep 
disturbances. These relationships were characterized in a sample of midlife women, as midlife 
women are at increased risk for depressive symptoms (Cohen et al., 2006), weight gain 
(Karvonen-Gutierrez & Kim, 2016), a decrease in physical activity (Center for Disease Control 
and Prevention, 2016), and sleep disturbances (Kravitz et al., 2017). Understanding the 
antecedents of sleep disturbances is critical because sleep disturbances are associated with 
increased risk for cardiovascular disease (Cappuccio, Cooper, Delia, Strazzullo, & Miller, 2011) 
and mortality (Cappuccio, D’Elia, Strazzullo, & Miller, 2010).  
In the current study, we report that higher mean depressive symptoms were longitudinally 
associated with poorer sleep health. This association was independent of known risk factors of 
sleep disturbances in midlife women, including age, race/ethnicity, vasomotor symptoms, 
antidepressant use, medications that affect sleep, and AHI. Additionally, BMI and physical 
activity were significant mediators of this pathway. There was a significant association between 
variability in depressive symptoms and sleep health in unadjusted, but not adjusted models. Our 
findings are of clinical importance, as they provide the foundation for future studies to evaluate 
whether a weight-loss or physical activity intervention in midlife women with depression may 
improve multiple dimensions of their sleep (e.g. regularity, efficiency), which may have 
important downstream consequences for cardiovascular health.  
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Sleep health is important to empirically test, as this emerging method integrates sleep, 
circadian rhythms, and functioning (Buysse, 2014). Sleep health accounts for the inherent 
interrelatedness of its variables. For example, if time in bed is held constant, increases in sleep 
efficiency are associated with an increase in sleep duration. Moreover, proximal measures of 
circadian rhythms are included, as sleep continuity and duration are partially due to the influence 
of circadian rhythms (Czeisler et al., 1980). Additionally, sleep health includes measures of the 
impact of sleep on next-day functioning. Since there is significant inter-individual variability in 
sleep need, the same sleep duration can result in differential physiological restoration across 
individuals (for review, see Van Dongen, Vitellaro, & Dinges, 2005). Because of these strengths, 
sleep health has been used in several previous studies (Brindle et al., 2018; Furihata et al., 2017). 
Untested in previous studies is whether the six components of sleep health are best 
characterized using equal or variable weighting (i.e. components that are more strongly 
associated with the predictor receive greater weighting). In the current study, we evaluated 
whether mean depressive symptoms was differentially associated with each sleep health 
component. Although mean depressive symptoms was more strongly associated with self-
reported satisfaction and alertness than the other components, these associations were not 
substantially different to merit variable weighting. This finding supports the rationale of previous 
studies which used equal weighting for sleep health (Brindle et al., 2018; Furihata et al., 2017). 
Testing for differential associations in future studies is important, because this may enhance the 
precision of predicted associations between sleep health and both its antecedents and 
consequences. It may be, as our study found, that sleep health should truly be equally weighted. 
Our study contributes to emerging evidence that sleep health is a promising construct for 
holistically evaluating sleep, circadian rhythms, and next-day functioning. 
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Higher mean depressive symptoms was longitudinally associated with poorer sleep 
health. In evaluation of the components of sleep health, higher depressive symptoms were 
associated with lower odds of optimal self-reported alertness and lower odds of optimal self-
reported sleep satisfaction in both unadjusted and adjusted models. This study replicates previous 
evidence that higher depressive symptoms are related to lower sleep satisfaction (Pien et al., 
2008) and less alertness at five-year follow-up (Lampio et al., 2016) among midlife women. 
Contrary to our expectations, mean depressive symptoms was not significantly associated with 
our measures of actigraphy-assessed sleep (duration and efficiency), and was only associated 
with proximal measures of circadian rhythms (timing and regularity) in unadjusted, but not 
adjusted, models. One possible explanation for these differential associations is that negative 
affect biases the self-report of sleep in individuals with higher depressive symptoms. That is, 
women with higher past depressive symptoms may be more likely to perceive their sleep as poor. 
Another explanation may be that depressive symptoms prospectively affect next-day functioning 
(alertness and satisfaction), but do not impact nocturnal sleep or circadian rhythms. This latter 
explanation would contrast with a large and consistent literature demonstrating an association 
between depression and sleep and circadian rhythms (Bao et al., 2017; McClung, 2013). To 
empirically test these two explanations, future research might compare a self-report sleep health 
construct to a behaviorally-assessed sleep health construct, which would include objective 
measures of next-day functioning (e.g. performance on the psychomotor vigilance task, an 
objective measure of alertness; Dinges & Powell, 1985). Additionally, a novel clinical 
intervention might provide individuals with higher depressive symptoms with feedback from 
actigraphy assessments to evaluate whether this changes perception of sleep satisfaction and 
alertness (see Tang & Harvey, 2004, for evidence that actigraphy feedback can improve 
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perceptions of sleep). Consistent with our hypothesis, we report that higher depressive symptoms 
is a significant antecedent of poorer sleep health in midlife women. 
 We evaluated physical activity and BMI as plausible biobehavioral mediators of the 
significant association between higher depressive symptoms and poorer sleep health. Mounting 
evidence suggests that cognitive behavioral therapy for depression improves sleep quality 
(Carney, Segal, Edinger, & Krystal, 2007), and therefore understanding how depression disrupts 
sleep may improve the precision of therapeutic interventions. Importantly, we assessed 
depressive symptoms two years before our mediators, and we measured our mediators two years 
before the sleep study. This approach provides temporal precedence.  
 Body mass index was a significant mediator of the relationship between higher 
depressive symptoms and poorer sleep health. Greater mean depressive symptoms was 
prospectively associated with higher BMI, which is consistent with meta-analytic evidence 
suggesting that depression is prospectively associated with an increase in BMI (Luppino et al., 
2010). Higher BMI was associated with poorer sleep health, which corroborates previous work 
suggesting similar associations (Resta et al., 2003; Vgontzas et al., 2003). If this were replicated, 
a weight-loss intervention designed for midlife women with depression would be expected to 
have benefits for sleep health. Emerging evidence suggests that individuals with depression are 
less responsive to standard weight-loss interventions (Pagoto et al., 2007), and thus an 
intervention tailored to midlife women with depression is needed for this population at-risk for 
poor sleep health.  
 Physical activity was also a significant mediator that explained some of the variance of 
the association between higher mean depressive symptoms and poorer sleep health. This finding 
is consistent with meta-analytic evidence that higher depressive symptoms are prospective 
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associated with lower physical activity (Roshanaei-Moghaddam, Katon, & Russo, 2009), and 
that lower physical activity is associated with poorer sleep (Kredlow et al., 2015). These data 
provide preliminary support for a physical activity intervention in individuals with depression to 
prevent or improve sleep outcomes. This intervention strategy seems reasonable, as a previous 
randomized controlled trial showed that a physical activity intervention improved sleep 
characteristics in a sample of individuals with insomnia (Reid et al., 2010). Unknown is the role 
that a physical activity intervention would have on the sleep of individuals with depression. 
Because the association between higher depressive symptoms and sleep health was not 
fully explained by physical activity or BMI, other modifiable mediators of the association are 
important to evaluate to improve interventions for midlife woman. One pathway may be through 
vasomotor symptoms. Longitudinal evidence has suggested that depressive symptoms precede 
incident vasomotor symptoms (Freeman, Sammel, & Lin, 2009), and vasomotor symptoms have 
been shown to affect sleep continuity (Thurston, Santoro, & Matthews, 2012). Another possible 
mediator may be social support. Depression has been shown to be prospectively associated with 
decreases in social support (Stice, Ragan, & Randall, 2004), while perceived loneliness has been 
associated with greater actigraphy-assessed sleep fragmentation (Kurina et al., 2011). In 
summary, our study provides preliminary evidence that accounting for physical activity partially 
explains the link between depressive symptoms and sleep disturbances in midlife women, and 
suggests that other modifiable biobehavioral mediators warrant further investigation.  
Variability in depressive symptoms was not significantly related to sleep health in 
adjusted models, nor was variability in depressive symptoms a significant moderator of the 
association between mean depressive symptoms and sleep health. One possible reason for this 
non-significant result is that higher mean level, but not higher variability in, depressive 
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symptoms may truly be what is negatively impacting sleep in midlife women. Several previous 
studies have reported that higher mean level, but not variability in, depressive symptoms is 
associated with greater risk of insomnia symptoms (Lampio et al., 2016; Woods & Mitchell, 
2010). Future studies with larger ranges in variability in depressive symptoms would help to 
clarify the role of both mean level and variability in depressive symptoms and possibly 
determine whether variability is unrelated to sleep disturbances in midlife women. 
Because sleep health is an emerging construct, we evaluated the relationships between 
covariates and sleep health. Race, menopausal status, and AHI were consistent, significant 
correlates of sleep health in the present sample of midlife women. African American women had 
poorer sleep health compared to European American. This is consistent with a meta-analysis of 
14 studies reporting that African Americans have less deep sleep, poorer sleep continuity, and 
shorter sleep duration compared to European Americans (Ruiter, DeCoster, Jacobs, & Lichstein, 
2011). Late perimenopausal status, relative to premenopausal status, was associated with poorer 
sleep health. This is consistent with a meta-analysis of 21 studies reporting that perimenopause 
(early or late) was associated with 1.60 greater odds of self-reported insomnia symptoms 
compared to premenopausal women (Xu & Lang, 2014). Higher AHI scores were associated 
with poorer sleep health. This result is unsurprising, as excessive daytime sleepiness and fatigue 
are common symptoms of obstructive sleep apnea due to intermittent hypoxia and increased 
sleep fragmentation (American Psychiatric Association, 2013). In sum, race, menopausal status, 
and AHI may be important correlates of sleep health in midlife women. 
4.1 Study design considerations 
Several limitations of the current study should be noted. First, although longitudinal, our study 
cannot be used to infer causality. The dynamics between depressive symptoms, physical activity, 
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and sleep health may occur on a different time scale than what we measured (i.e. occurring at the 
monthly level rather than over two years). There may also be additional variables that were not 
accounted for in our study. Second, our results do not generalize to middle-aged men, nor to 
older or younger age groups. Midlife for women is characterized by menopause, which causes 
unique changes in hormones and physiology that are not present in other populations. Third, our 
sample is limited in its range of mean and variability in depressive symptoms. A longitudinal 
study that oversampled midlife women with depressive symptoms would more effectively 
examine these relationships. 
The present study has notable strengths. First, the study evaluates sleep using actigraphy, 
measuring habitual rest-activity patterns in participants’ natural environment for nearly a month 
(M = 29 days). Second, our study evaluates putative mediators of the association between 
depressive symptoms and sleep health with clear temporal precedence. The model tests 
depressive symptoms averaged over four years, then assesses BMI and physical activity two 
years later, and then sleep health two years later. Third, our results did not substantially change 
when we used multiple imputation to address missing data. It was plausible that women with 
higher mean depressive symptoms might be less likely to attend a core SWAN follow-up visit, 
which might account for the missingness. Given the longitudinal nature of the core SWAN study, 
we had the opportunity to create imputations based on six to nine visits of data, which improves 
the plausibility of estimates.  
In conclusion, higher mean depressive symptoms was prospectively associated with 
poorer sleep health in a sample of midlife women. Physical activity and BMI were significant 
mediators of the association. These antecedents of sleep disturbances are noteworthy, given the 
prevalence of clinically significant depressive symptoms, obesity, and inadequate regular 
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physical activity in midlife women. However, depressive symptoms, weight, and physical 
activity are modifiable risk factors, and interventions designed to target these factors may be 
well-suited for improving sleep disturbances and the subsequent effect of sleep on adverse health 
outcomes, including diabetes, cardiovascular disease, and early mortality. 
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Appendix A. Tables and Figures  
 
Table 1. Sleep health cut-offs. 
Sleep Health 
Component 
Operationalization Cut-off for optimal sleep health 
Regularity Standard deviation of 
calculated sleep midpoint 
from actigraphy 
Less than 60 minutes1-3 
 
Satisfaction Average self-reported sleep 
quality from daily sleep 
diary, “restedness upon 
awakening” (0 = not at all; 4 
= extremely) 
 “Moderately”, “quite a bit”, or 
“extremely” rested upon 
awakening4 
Alertness Total score on Epworth 
Sleepiness Scale (0-24) 
Less than 105 
Timing Average calculated sleep 
midpoint from actigraphy 
2am – 4am2,6-7  
 
Efficiency Average sleep efficiency 
from actigraphy 
Greater than 85%8 
Duration Average total sleep time 
from actigraphy 
6 to 8 hours9 
 
Note. 1Roenneberg, Allebrandt, Merrow, & Vetter, 2012; 2Wittmann, Dinich, Merrow, 
& Roenneberg, 2006; 3Wong, Hasler, Kamarck, Muldoon, & Manuck, 2015; 4Furihata 
et al, 2017, defined poor sleep health as reporting not getting enough sleep often (5-
15nights/month) or almost always (16-30nights/month); 5Johns, 1991; 6 Baron, Reid, 
Kern, & Zee, 2011; 7Roenneberg et al., 2007; 8Spielman, Saskin, & Thorpy, 1987 
9Watson et al., 2015, we modified their self-reported sleep duration recommendations 
to reflect the fact that actigraphy assessed sleep duration is typically approximately one 
hour less than self-reported sleep duration (Lauderdale et al., 2008). 
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Table 2. Sample Characteristics. 
 M (SD) N (%) 
Mean depressive symptoms, CES-D 7.5 (6.2)  
Variability in depressive symptoms, CES-D 4.5 (3.0)  
Body mass index 29.8 (7.9)  
Kaiser Physical Activity Survey 7.5 (1.7)  
Age 52.1 (2.1)  
Race/ethnicity   
European American  140 (46.4) 
African American  112 (37.1) 
Chinese American  50 (16.6) 
Study site   
Pittsburgh, PA  76 (25.2) 
Detroit area, MI  60 (19.9) 
Chicago, IL  71 (23.5) 
Oakland, CA  95 (31.5) 
Menopausal status   
Pre-/early perimenopausal  187 (61.9) 
Late perimenopausal  58 (19.2) 
Postmenopausal  38 (12.6) 
Unknown  19 (6.3) 
Antidepressant history, proportion of visits 0.11 (0.25)  
Vasomotor symptoms, % of study nights 32.8 (34.1)  
Sleep medications, % of study nights 23.7 (41.3)  
Apnea-hypopnea index 10.5 (15.6)  
Notes. Center for Epidemiological Studies Depression Scale, CES-D; CES-D clinical cut-off > 
16, Kaiser Physical Activity Scale scores range 0-15, with higher scores indicating more 
activity. 
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Table 3. Sleep health characteristics. 
Continuous sleep variable M (SD) Sleep health  Optimal, N (%) 
Sleep duration, hours, actigraphy 6.0 (0.9) Duration 145 (48) 
Sleep efficiency, actigraphy 78.0 (10.2) Efficiency 73 (24.2) 
Sleep midpoint, actigraphy 3:20a (0:33) Timing 265 (87.7) 
Standard deviation midpoint, actigraphy 42 (18) Regularity 245 (81.1) 
Restedness, diary 2.0 (0.6) Satisfaction 162 (53.6) 
Sleepiness, Epworth Sleepiness Scale 7.7 (4.4) Alertness 209 (69.2) 
Notes. Optimal indicates optimal sleep health for each component.  
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Table 4. Mean depressive symptoms and sleep health. 
Unadjusted model β p 
Mean depressive symptoms, CES-D -0.30 <.001 
Adjusted model   
Mean depressive symptoms, CES-D -0.24 <.001 
Age -0.02 .70 
Race/ethnicity   
European American Reference  
African American -0.17 .009 
Chinese American -0.13 .07 
Study site   
Pittsburgh, PA Reference  
Detroit area, MI -0.12 .06 
Chicago, IL -0.03 .69 
Oakland, CA 0.14 .10 
Menopausal status   
Pre-/early perimenopausal Reference  
Late perimenopausal -0.11 .05 
Postmenopausal 0.01 .86 
Unknown -0.07 .22 
Antidepressants, proportion of visits 0.03 .62 
Vasomotor symptoms, % -0.03 .58 
Sleep medications, % -0.07 .25 
Apnea-hypopnea index -0.18 .001 
Notes. Center for Epidemiological Studies Depression Scale, CES-D; Adjusted model indicates 
that the model includes all covariates 
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Table 5. Variability in depressive symptoms and sleep health. 
Unadjusted model β p 
Variability in depressive symptoms, CES-D -0.14 .02 
Adjusted model   
Variability in depressive symptoms, CES-D -0.08 .16 
Age -0.02 .70 
Race/ethnicity   
European American Reference  
African American -0.18 .008 
Chinese American -0.13 .07 
Study site   
Pittsburgh, PA Reference  
Detroit area, MI -0.16 .01 
Chicago, IL -0.04 .56 
Oakland, CA 0.13 .13 
Menopausal status   
Pre-/early perimenopausal Reference  
Late perimenopausal -0.09 .11 
Postmenopausal 0.01 .89 
Unknown -0.07 .21 
Antidepressants, proportion of visits -0.02 .79 
Vasomotor symptoms, % -0.07 .23 
Sleep medications, % -0.04 .48 
Apnea-hypopnea index -0.18 .001 
Notes. Center for Epidemiological Studies Depression Scale, CES-D; Adjusted model indicates 
that the model includes all covariates; vasomotor symptoms, VMS; apnea hypopnea index, AHI 
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Table 6. Moderation models. 
 Model 1 Model 2 Model 3 Model 4 
 Basic Model 
(Mean only) 
Mean, 
variability 
Mean, 
variability, 
and 
Interaction 
Fully adjusted 
model 
 β p β p β p β p 
Mean depressive symptoms, CES-D -0.30 <.001 -0.29 .001 -0.29 .001 -0.27 .001 
Variability in depressive symptoms, CES-D   0.09 .26 0.09 .32 0.11 .19 
Mean X Variability, CES-D     0.02 .78 0.01 .82 
Age       0.01 .93 
Race/ethnicity         
     European American       Ref  
     African American       -0.19 .005 
     Chinese American       -0.15 .05 
Study site         
     Pittsburgh, PA       Ref  
     Detroit area, MI       -0.13 .05 
     Chicago, IL       0.01 .91 
     Oakland, CA       0.17 .06 
Menopausal status         
     Pre-/early perimenopausal       Ref  
     Late perimenopausal       -0.15 .01 
     Postmenopausal       -0.02 .73 
     Unknown       -0.06 .31 
Antidepressants, proportion of visits       0.02 .78 
Vasomotor symptoms, % of study nights       -0.03 .62 
Sleep medications, % of study nights       -0.07 .27 
Apnea-hypopnea index       -0.15 .01 
Notes. Center for Epidemiological Studies Depression Scale, CES-D; interaction term, Mean X Variability; 
Adjusted model indicates that the model includes all covariates. 
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Baseline 
Visit 1 
Visit 2 
Visit 3 
Visit 4 
Visit 5 
Visit 6 
Visit 7 
Visit 8 
Sleep Study 
(a) Data structure for the full sample. Depressive symptoms were assessed from baseline 
(1996-1997) until the visit preceding the SWAN Sleep Study (follow-up visits 5-8). The 
SWAN Sleep Study occurred 2001-2006. 
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Baseline 
Visit 1 
Visit 2 
Visit 3 
Visit 4 
Visit 5 
Visit 6 
Sleep 
Study 
Average 7 visits of 
CES-D data 
collected over 5.7 
years 
Average 5.7 months 
follow-up time between 
last depression assessment 
and Sleep Study 
(b) Data structure for the average participant in the sample for Aim 1. The average and 
standard deviation of depressive symptoms were calculated over all visits preceding the 
SWAN Sleep Study. 
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CES-D 
CES-D 
CES-D 
CES-D 
- 
BMI/PA 
- 
Sleep 
Study 
Average 2 years between 
BMI/PA assessment and 
Sleep Study 
Average 2 years between 
CES-D assessment and 
BMI/PA assessment 
(c) Data structure for all participants for Aim 2. Depressive symptoms, assessed using the 
Center for Epidemiological Studies Depression Scale (CES-D), was measured at four visits. 
Two years later, body mass index (BMI) and physical activity (PA) were measured. Two 
years later, sleep health was measured at the SWAN sleep study. 
Figure 1. Visualizing the structure of the core SWAN study and the ancillary SWAN Sleep 
Study. 
(a) depicts the structure of the data overall; (b) depicts the structure of the data for the average 
participant for Aim 1; (c) depicts the structure of the data for all participants for Aim 2. 
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Figure 2. Data reduction strategy. 
  
Consented to the SWAN Sleep 
Study (n = 370) 
Have > 4 nights of actigraphy 
data (n = 328) 
Excluded due to zero nights of 
actigraphy data (n = 38) or only 
1-3 nights (n = 4) 
Have > 4 nights of actigraphy and 
Epworth Sleepiness Scale data  
(n = 319) 
Excluded due to missing Epworth 
Sleepiness Scale (n = 9) 
Excluded due to missing apnea 
hypopnea index (n = 17) 
Have > 4 nights of actigraphy, 
Epworth Sleepiness Scale, and 
apnea hypopnea index data   
(n = 302) 
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Figure 3. Distribution of sleep health. 
Note that the percentage of participants in each category is depicted. Possible sleep health values 
range from 0-6. 
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Figure 4. Percent of women with optimal sleep health for each sleep health component. 
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Figure 5. Mean depressive symptoms and individual components of sleep health. 
Figure depicts adjusted models, which include the following covariates: age, race (African 
American and Chinese American as dummy variables, European American as reference), site 
(Detroit, Oakland, and Chicago as dummy variables, Pittsburgh as reference), menopausal status 
(late perimenopause, postmenopause, and unknown as dummy variable, pre- and early peri-
menopause as reference), antidepressant use (proportion of visits before the sleep study), 
vasomotor symptoms (% of study nights), medications that affect sleep (% of study nights), and 
apnea hypopnea index. 
  
0.8 0.9 1 1.1 1.2
Duration
Efficiency
Timing
Regularity
Satisfaction
Alertness
Odds Ratio
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Figure 6. Variability in depressive symptoms and individual components of sleep health. 
Figure depicts adjusted models, which include the following covariates: age, race (African 
American and Chinese American as dummy variables, European American as reference), site 
(Detroit, Oakland, and Chicago as dummy variables, Pittsburgh as reference), menopausal status 
(late perimenopause, postmenopause, and unknown as dummy variable, pre- and early peri-
menopause as reference), antidepressant use (proportion of visits before the sleep study), 
vasomotor symptoms (% of study nights), medications that affect sleep (% of study nights), and 
apnea hypopnea index. 
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Figure 7. Mediation models. 
Parallel multiple mediation model linking depressive symptoms to sleep health through body 
mass index and physical activity. Coefficients are shown for each path, and * indicates 
significance using a 95% confidence interval. The solid line indicates significant partial 
mediation. The dotted line indicates that there is a significant indirect effect, but not significant 
mediation. The direct effect of depression on sleep health after adjusting for the indirect effects is 
shown. 
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Appendix B. Supplemental Tables and Figures 
Table S1. Variably weighted sleep health. 
Odds Ratio 
Regularity 1.03 
Satisfaction 1.09* 
Alertness 1.09* 
Timing 1.11* 
Efficiency 1.01 
Duration 0.99 
Note. Sleep health was inverted so that higher values 
indicated worse sleep health. Mean depressive symptoms 
was the predictor in each model. * indicates p < .05 
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Table S2. Comparing observed and imputed CES-D descriptive statistics. 
 Number Min Max Mean SD Variance 
CES-D 0       
     Observed 319 0 45 9.12 8.78 77.00 
     Imputed - - - - - - 
CES-D 1       
Observed 309 0 43 7.57 7.85 61.64 
Imputed 6380 0 43 7.60 7.75 60.06 
CES-D 2       
Observed 305 0 55 7.23 7.82 61.20 
Imputed 6380 0 55 7.23 7.68 59.00 
CES-D 3       
Observed 314 0 48 7.06 8.14 66.18 
Imputed 6380 0 48 7.06 8.07 65.14 
CES-D 4       
Observed 309 0 36 7.06 8.14 66.18 
Imputed 6380 0 36 7.32 7.71 59.46 
CES-D 5       
Observed 311 0 44 6.95 7.46 55.65 
Imputed 6380 0 44 6.93 7.38 54.40 
CES-D 6       
Observed 310 0 39 7.06 7.68 59.02 
Imputed 6380 0 39 7.06 7.59 57.64 
CES-D 7       
Observed 297 0 49 5.91 7.03 49.42 
Imputed 6380 0 49 5.93 6.84 46.77 
CES-D 8       
Observed 284 0 38 6.34 6.96 48.51 
Imputed 6380 0 38 6.36 6.68 44.58 
Note. Center for Epidemiological Studies – Depression Scale, sleep item removed, CES-D; Number of 
observations, number; Standard deviation, SD. CES-D 0 was not imputed because data was available 
for all participants. 
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Table S3. Comparing observed and imputed covariate descriptive statistics. 
 Number Min Max Mean SD Variance 
Mean, CESD       
Observed 319 0.13 38.57 7.38 6.16 37.92 
Imputed 6380 0.13 38.57 6.59 4.81 23.15 
Variability, CES-D       
Observed 319 0.35 16.75 4.48 2.99 8.91 
Imputed 6380 0.35 16.75 4.48 2.98 8.88 
BMI 5       
Observed 303 17.53 55.68 29.86 7.90 62.36 
Imputed 6380 17.53 55.68 29.84 7.86 61.85 
KPAS 5       
Observed 292 3.40 12.45 7.54 1.72 2.96 
Imputed 6380 3.00 12.45 7.53 1.72 2.96 
Apnea hypopnea index       
Observed 302 0 119.71 10.51 15.56 242.16 
Imputed 6380 0 119.71 10.82 15.43 238.23 
Notes. Center for Epidemiological Studies – Depression Scale, CES-D; Body Mass Index, BMI; Kaiser 
Physical Activity Survey, KPAS; Number of observations, number; Standard deviation, SD.  
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Table S4. Sample characteristics comparing listwise deletion to multiple imputation strategies. 
 Listwise deletion Multiple imputation 
Mean depressive symptoms, mean (SD) 7.5 (6.2) 7.4 (7.9) 
Variability in depressive symptoms CES-D, mean (SD) 4.5 (3.0) 4.5 (3.0) 
Body mass index, mean (SD) 29.8 (7.9) 29.8 (7.9) 
Kaiser Physical Activity Survey, mean (SD) 7.5 (1.7) 7.5 (1.7) 
Age, mean (SD) 52.1 (2.1) 52.2 (2.1) 
Race/ethnicity   
White, n (%) 140 (46.4) 148 (46.4) 
African American, n (%) 112 (37.1) 119 (37.3) 
Chinese, n (%) 50 (16.6) 52 (16.3) 
Study site   
Pittsburgh, PA, n (%) 76 (25.2) 84 (26.3) 
Detroit area, MI, n (%) 60 (19.9) 64 (26.3) 
Chicago, IL, n (%) 71 (23.5) 73 (22.9) 
Oakland, CA, n (%) 95 (31.5) 98 (30.7) 
Menopausal status   
Pre-/early perimenopausal, n (%) 187 (61.9) 196 (61.4) 
Late perimenopausal, n (%) 58 (19.2) 63 (19.7) 
Postmenopausal, n (%) 38 (12.6) 40 (12.5) 
Unknown, n (%) 19 (6.3) 20 (6.3) 
Antidepressant history, proportion of visits, mean (SD) 0.11 (0.25) 0.12 (0.25) 
Sleep medications, % of study nights, mean (SD) 32.8 (34.1) 24.7 (41.9) 
Vasomotor symptoms, % of study nights, mean (SD) 23.7 (41.3) 33.4 (34.4) 
Apnea hypopnea, index, mean (SD) 10.5 (15.6) 10.8 (15.4) 
Notes. Center for Epidemiological Studies Depression Scale, CES-D; CES-D clinical cut-off > 
16, Kaiser Physical Activity Scale scores range 0-15, with higher scores indicating more 
activity. 
 
 
 
Table S5. Sleep health characteristics comparing listwise deletion to multiple imputation strategies. 
 Listwise deletion (n = 302) Multiple imputation (n = 319) 
Sleep health  M (SD) Optimal, N (%) M (SD) Optimal, N (%) 
Duration 6.0 (0.9) 145 (48) 5.9 (1.0) 154 (48.3) 
Efficiency 78.0 (10.2) 73 (24.2) 77.2 (10.8) 78 (24.5) 
Timing 3:20a (0:33) 265 (87.7) 3:22a (0:33) 280 (87.8) 
Regularity 42.3 (18.3) 245 (81.1) 45.2 (20.2) 258 (80.9) 
Satisfaction 2.0 (0.6) 162 (53.6) 2.0 (0.6) 173 (54.2) 
Alertness 7.7 (4.4) 209 (69.2) 7.6 (4.3) 225 (70.5) 
Notes. Optimal indicates optimal sleep health for each component. 
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Table S6. Mean depressive symptoms and sleep health in the multiple imputation dataset. 
Unadjusted model β p 
Mean depressive symptoms, CES-D -0.30 <.001 
Adjusted model   
Mean depressive symptoms, CES-D -0.30 <.001 
Age -0.03 .60 
Race/ethnicity   
European American Reference  
African American -0.19 .002 
Chinese American -0.12 .08 
Study site   
Pittsburgh, PA Reference  
Detroit area, MI -0.14 .03 
Chicago, IL -0.05 .42 
Oakland, CA 0.10 .21 
Menopausal status   
Pre-/early perimenopausal Reference  
Late perimenopausal -0.08 .13 
Postmenopausal 0.02 .79 
Antidepressants, proportion of visits -0.01 .97 
Vasomotor symptoms, % of study nights -0.03 .58 
Sleep medications, % of study nights -0.06 .34 
Apnea-hypopnea index -0.19 <.001 
Notes. Center for Epidemiological Studies Depression Scale, CES-D; Adjusted model indicates 
that the model includes all covariates.  
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Table S7. Variability in depressive symptoms and sleep health in the multiple imputation dataset. 
Unadjusted model β p 
Variability in CES-D -0.13 .02 
Adjusted model   
Variability in CES-D -0.05 .17 
Age 0.01 .66 
Race/ethnicity   
European American Reference  
African American -0.22 .002 
Chinese American -0.14 .07 
Study site   
Pittsburgh, PA Reference  
Detroit area, MI -0.17 .006 
Chicago, IL -0.06 .33 
Oakland, CA 0.10 .25 
Menopausal status   
Pre-/early perimenopausal Reference  
Late perimenopausal -0.07 .25 
Postmenopausal 0.01 .89 
Unknown -0.09 .11 
Antidepressants, proportion of visits -0.05 .43 
Vasomotor symptoms, % of study nights -0.07 .24 
Sleep medications, % of study nights -0.03 .60 
Apnea-hypopnea index -0.21 <.001 
Notes. Center for Epidemiological Studies Depression Scale, CES-D; Adjusted model indicates 
that the model includes all covariates; vasomotor symptoms, VMS; apnea hypopnea index, AHI 
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Table S8. Moderation models in the multiple imputation dataset. 
 Model 1 Model 2 Model 3 Model 4 
 Basic Model 
(Mean only) 
Mean, 
variability 
Mean, 
variability, 
and 
Interaction 
Fully adjusted 
model 
 β p β p β p β p 
Mean depressive symptoms, CES-D -0.27 <.001 -0.35 <.001 -0.34 .001 -0.30 .002 
Variability in depressive symptoms, CES-D   0.10 .26 0.10 .26 0.12 .16 
Mean X Variability, CES-D     -0.02 .69 -0.02 .75 
Age       0.01 .93 
Race/ethnicity         
     European American       Ref  
     African American       -0.20 .003 
     Chinese American       -0.14 .04 
Study site         
     Pittsburgh, PA       Ref  
     Detroit area, MI       -0.14 .04 
     Chicago, IL       0.01 .99 
     Oakland, CA       0.16 .06 
Menopausal status         
     Pre-/early perimenopausal       Ref  
     Late perimenopausal       -0.13 .03 
     Postmenopausal       -0.03 .64 
     Unknown       -0.07 .24 
Antidepressants, proportion of visits       0.02 .73 
Vasomotor symptoms, % of study nights       -0.04 .57 
Sleep medications, % of study nights       -0.08 .22 
Apnea-hypopnea index       -0.19 .002 
Notes. Center for Epidemiological Studies Depression Scale, CES-D; interaction term, Mean X Variability; 
Adjusted model indicates that the model includes all covariates. 
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Figure S1. Mean depressive symptoms and individual components of sleep health in adjusted 
models in the multiple imputation dataset. 
Figure depicts adjusted models, which include the following covariates: age, race (African 
American and Chinese American as dummy variables, European American as reference), site 
(Detroit, Oakland, and Chicago as dummy variables, Pittsburgh as reference), menopausal status 
(late perimenopause, postmenopause, and unknown as dummy variable, pre- and early peri-
menopause as reference), antidepressant use (proportion of visits before the sleep study), 
vasomotor symptoms (% of study nights), medications that affect sleep (% of study nights), and 
apnea hypopnea index. 
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Figure S2. Variability in depressive symptoms and individual sleep health components in 
adjusted models in the multiple imputation dataset. 
Figure depicts adjusted models, which include the following covariates: age, race (African 
American and Chinese American as dummy variables, European American as reference), site 
(Detroit, Oakland, and Chicago as dummy variables, Pittsburgh as reference), menopausal status 
(late perimenopause, postmenopause, and unknown as dummy variable, pre- and early peri-
menopause as reference), antidepressant use (proportion of visits before the sleep study), 
vasomotor symptoms (% of study nights), medications that affect sleep (% of study nights), and 
apnea hypopnea index. 
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Figure S3. Mediation models. 
Parallel multiple mediation model linking depressive symptoms to sleep health through body 
mass index and physical activity, in the multiple imputation dataset. Coefficients are shown for 
each path, and * indicates significance using a 95% confidence interval. The solid line indicates 
significant partial mediation. The dotted line indicates that there is a significant indirect effect, 
but not significant mediation. The direct effect of depression on sleep health after adjusting for 
the indirect effects is shown. 
 
